Nan‐Horng Lin

2.9k total citations
67 papers, 2.1k citations indexed

About

Nan‐Horng Lin is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Nan‐Horng Lin has authored 67 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Molecular Biology, 29 papers in Organic Chemistry and 21 papers in Pharmacology. Recurrent topics in Nan‐Horng Lin's work include Nicotinic Acetylcholine Receptors Study (22 papers), Cholinesterase and Neurodegenerative Diseases (19 papers) and Cancer-related Molecular Pathways (17 papers). Nan‐Horng Lin is often cited by papers focused on Nicotinic Acetylcholine Receptors Study (22 papers), Cholinesterase and Neurodegenerative Diseases (19 papers) and Cancer-related Molecular Pathways (17 papers). Nan‐Horng Lin collaborates with scholars based in United States, United Kingdom and Taiwan. Nan‐Horng Lin's co-authors include Zhi‐Fu Tao, Mark W. Holladay, David J. Anderson, Saul H. Rosenberg, Stephen P. Arnerić, Yun He, Thomas J. Sowin, James P. Sullivan, Hing L. Sham and Haiying Zhang and has published in prestigious journals such as Journal of the American Chemical Society, Chemical Communications and Clinical Cancer Research.

In The Last Decade

Nan‐Horng Lin

67 papers receiving 2.1k citations

Peers

Countries citing papers authored by Nan‐Horng Lin

Since Specialization

Citations

This map shows the geographic impact of Nan‐Horng Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan‐Horng Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan‐Horng Lin more than expected).

Fields of papers citing papers by Nan‐Horng Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nan‐Horng Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan‐Horng Lin. The network helps show where Nan‐Horng Lin may publish in the future.

Co-authorship network of co-authors of Nan‐Horng Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Nan‐Horng Lin. A scholar is included among the top collaborators of Nan‐Horng Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nan‐Horng Lin. Nan‐Horng Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of glycosynthases with broad glycan specificity for the efficient glyco-remodeling of antibodies 2018 ·Chemical Communications ·Sachin S. Shivatare, Lin‐Ya Huang, Yi‐Fang Zeng, (unknown), (unknown), Shiyun Wang, (unknown), Chih‐Wei Chiu, Ping Chao, (unknown), Tsung-I Tsai, Chiu-Chen Huang, Chung‐Yi Wu, Nan‐Horng Lin, Chi‐Huey Wong	30
2	Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors 2008 ·Biomarkers ·Zhan Xiao, John Xue, Wen‐Zhen Gu, Mai H. Bui, Gaoquan Li, Zhi‐Fu Tao, Nan‐Horng Lin, Thomas J. Sowin, Haiying Zhang	20
3	Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Lisa Hasvold, Le Wang, (unknown), Zhan Xiao, Zehan Chen, Wen‐Zhen Gu, Philip J. Merta, John Xue, Peter Kovar, Haiying Zhang, Chang Park, Thomas J. Sowin, Saul H. Rosenberg, Nan‐Horng Lin	10
4	Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: Improving oral biovailability 2007 ·Bioorganic & Medicinal Chemistry Letters ·Yunsong Tong, (unknown), Zhi‐Fu Tao, Jennifer J. Bouska, Kent D. Stewart, Chang Park, Gaoquan Li, Akiyo Claiborne, Peter Kovar, Zehan Chen, Philip J. Merta, (unknown), Amanda M. Olson, Donald J. Osterling, Haiying Zhang, Hing L. Sham, Saul H. Rosenberg, Thomas J. Sowin, Nan‐Horng Lin	5
5	Macrocyclic ureas as potent and selective Chk1 inhibitors: An improved synthesis, kinome profiling, structure–activity relationships, and preliminary pharmacokinetics 2007 ·Bioorganic & Medicinal Chemistry Letters ·Zhi‐Fu Tao, Zehan Chen, (unknown), Peter Kovar, Eric F. Johnson, Jennifer J. Bouska, Haiying Zhang, Saul H. Rosenberg, Thomas J. Sowin, Nan‐Horng Lin	13
6	Synthesis and in-vitro biological activity of macrocyclic urea Chk1 inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Gaoquan Li, Zhi‐Fu Tao, Yunsong Tong, (unknown), Peter Kovar, Philip J. Merta, Zehan Chen, Haiying Zhang, Thomas J. Sowin, Saul H. Rosenberg, Nan‐Horng Lin	9
7	Synthesis and biological evaluation of 4′-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Zhi‐Fu Tao, Gaoquan Li, Yunsong Tong, Zehan Chen, Philip J. Merta, Peter Kovar, Haiying Zhang, Saul H. Rosenberg, Hing L. Sham, Thomas J. Sowin, Nan‐Horng Lin	22
8	Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·Gaoquan Li, Lisa Hasvold, Zhi‐Fu Tao, Gary T. Wang, Stephen L. Gwaltney, (unknown), Peter Kovar, R.B. Credo, Zehan Chen, Haiying Zhang, Chang Park, Hing L. Sham, Thomas J. Sowin, Saul H. Rosenberg, Nan‐Horng Lin	29
9	Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics 2006 ·International Journal of Cancer ·Zehan Chen, Zhan Xiao, Wen‐Zhen Gu, John Xue, Mai H. Bui, Peter Kovar, Gaoquan Li, Gary Wang, Zhi‐Fu Tao, Yunsong Tong, Nan‐Horng Lin, Hing L. Sham, Jean Y. J. Wang, Thomas J. Sowin, Saul H. Rosenberg, Haiying Zhang	103
10	Chk1 Inhibitors for Novel Cancer Treatment 2006 ·Anti-Cancer Agents in Medicinal Chemistry ·Zhi‐Fu Tao, Nan‐Horng Lin	71
11	Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors 2005 ·Bioorganic & Medicinal Chemistry Letters ·Qun Li, Keith W. Woods, Weibo Wang, Nan‐Horng Lin, Akiyo Claiborne, Wen‐Zhen Gu, Jerry D. Cohen, Vincent S. Stoll, Charles W. Hutchins, David J. Frost, Saul H. Rosenberg, Hing L. Sham	28
12	Synthesis of 1H-pyridin-2-one derivatives as potent and selective farnesyltransferase inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Nan‐Horng Lin, Qun Li, Rodger F. Henry, Haiying Zhang, Jerome Cohen, Wen‐Zhen Gu, Kennan C. Marsh, Joy Bauch, Saul H. Rosenberg, Hing L. Sham	10
13	ABT‐089: Pharmacological Properties of a Neuronal Nicotinic Acetylcholine Receptor Agonist for the Potential Treatment of Cognitive Disorders 2004 ·CNS Drug Reviews ·Lynne E. Rueter, David J. Anderson, Clark A. Briggs, Diana L. Donnelly‐Roberts, Gary A. Gintant, Murali Gopalakrishnan, Nan‐Horng Lin, Mark A. Osinski, Glenn A. Reinhart, Michael Buckley, Ruth L. Martin, Jeff S. McDermott, Lee C. Preusser, Terese Seifert, Zhi Su, Bryan F. Cox, Michael Decker, James P. Sullivan	57
14	Synthesis and biological evaluation of 4-[(3-Methyl-3H-imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-methyl]-benzonitrile as novel farnesyltransferase inhibitor 2003 ·Bioorganic & Medicinal Chemistry Letters ·Nan‐Horng Lin, Le Wang, Jerry D. Cohen, Wen‐Zhen Gu, David J. Frost, Haiying Zhang, Saul H. Rosenberg, Hing L. Sham	4
15	Pyridone-Containing farnesyltransferase inhibitors: synthesis and biological evaluation 2003 ·Bioorganic & Medicinal Chemistry Letters ·Lisa Hasvold, Weibo Wang, Stephen L. Gwaltney, Todd W. Rockway, Lissa T.J. Nelson, Robert A. Mantei, Stephen A. Fakhoury, Gerard M. Sullivan, Qun Li, Nan‐Horng Lin, (unknown), Haiying Zhang, Jerome Cohen, Wen‐Zhen Gu, Kennan C. Marsh, Joy Bauch, Saul H. Rosenberg, Hing L. Sham	64
16	Synthesis and biological evaluation of pyridine-modified analogues of 3-(2-Aminoethoxy)pyridine as novel nicotinic receptor ligands 2002 ·Bioorganic & Medicinal Chemistry Letters ·Nan‐Horng Lin, Liming Dong, William H. Bunnelle, David J. Anderson, Michael D. Meyer	9
17	Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework 1999 ·Bioorganic & Medicinal Chemistry Letters ·Nan‐Horng Lin, (unknown), David Gunn, Suzanne A. Lebold, Edmund Lee, James T. Wasicak, (unknown), Jerome F. Daanen, David S. Garvey, Jeffrey E. Campbell, (unknown), Michael T. Williams, Stephen P. Arnerić	12
18	ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties 1997 ·Journal of Pharmacology and Experimental Therapeutics ·James P. Sullivan, Diana L. Donnelly‐Roberts, (unknown), David J. Anderson, Murali Gopalakrishnan, (unknown), Marietta Piattoni-Kaplan, Eduardo Molinari, Jeffrey E. Campbell, David G. McKenna, David Gunn, Nan‐Horng Lin, Keith B. Ryther, Yun He, Mark W. Holladay, Susan Wonnacott, Michael T. Williams, Stephen P. Arnerić	70
19	Quantitative structure-activity relationships of nicotine analogues as neuronal nicotinic acetylcholine receptor ligands 1996 ·Bioorganic & Medicinal Chemistry ·Ki Hwan Kim, Nan‐Horng Lin, David J. Anderson	21
20	Ligands for Brain Cholinergic Channel Receptors: Synthesis and in Vitro Characterization of Novel Isoxazoles and Isothiazoles as Bioisosteric Replacements for the Pyridine Ring in Nicotine 1994 ·Journal of Medicinal Chemistry ·David S. Garvey, James T. Wasicak, Richard L. Elliott, Suzanne A. Lebold, (unknown), George M. Carrera, Nan‐Horng Lin, (unknown), Mark W. Holladay	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact